To include your compound in the COVID-19 Resource Center, submit it here.

Prevnar 13: Phase III data

The double-blind, international Phase III Study 3005 trial in 938 healthy adults >=70 years of age who had previously been vaccinated with Pneumovax 23 pneumococcal vaccine showed that a single dose of Prevnar 13 met the primary endpoint by demonstrating non-inferior immunogenicity compared to Pneumovax for the

Read the full 475 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers